Drugs / Inarigivir
Inarigivir
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03493698 | May → Aug 2018 | — | F-star Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Inarigivir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03493698 ↗ |
| Known as | Inarigivir Soproxil | “Inarigivir Soproxil, SB 9200” NCT03493698 ↗ |
| Known as | SB 9200 | “Inarigivir Soproxil, SB 9200” NCT03493698 ↗ |
| Route | Oral | “single oral dose of 400 mg Inarigivir on Day 3, Day 6-18” NCT03493698 ↗ |